BEUDAMED
    FDA Adverse Event Injury Summary report: N

    CLOSUREFAST CATHETER

    MDR report key: 13595664 · Received February 24, 2022

    Report

    Report Number
    2183870-2022-00064
    Event Type
    Injury
    Date Received
    February 24, 2022
    Date of Event
    February 1, 2022
    Report Date
    February 24, 2022
    Manufacturer
    COVIDIEN
    Product Code
    GEI
    PMA / PMN Number
    K111887
    Adverse Event
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    EI
    Reporter Occupation
    PHYSICIAN
    Health Professional
    Yes

    Narratives

    Additional Manufacturer Narrative · 0

    TITLE: OUTCOMES OF SAPHENOUS VEIN INTERVENTION IN THE MANAGEMENT OF SUPERFICIAL VENOUS INCOMPETENCE. A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS AUTHOR: SARA A. GASIOR, JOHN P. M. O¿DONNELL, THOMAS M. AHERNE. JOURNAL: ANNALS OF SURGERY YEAR: 2022 VOL/ISSUE: 275(2) REF: 10.1097/SLA.0000000000004914. DATE OF PUBLICATION JOURNAL REPORTED DEATH BUT THERE IS NO INFORMATION TO SUGGEST THE DEVICE CAUSED OR CONTRIBUTED TO THE DEATH EVENTS. DEATHS ARE COMMON OCCURRENCES IN CLINICAL STUDIES, HOWEVER THE CAUSE(S) OF DEATH ARE OFTEN NOT CHARACTERIZED OR CLEARLY ASSOCIATED WITH A PARTICULAR PRODUCT. THEREFORE, DEATHS WILL NOT BE CONSIDERED REPORTABLE UNLESS CLEARLY STATED AS BEING ASSOCIATED WITH A MEDTRONIC DEVICE. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

    Description of Event or Problem · 0

    A JOURNAL ARTICLE WAS SUBMITTED WITH THE OBJECTIVE TO DETERMINE THE MOST EFFECTIVE MODALITY OF INTERVENTION TO TREAT SAPHENOUS VEIN INSUFFICIENCY. A SYSTEMATIC REVIEW AND SERIES OF NETWORK META-ANALYSES OF RANDOMIZED CONTROLLED TRIALS (RCTS) WERE PERFORMED ASSESSING RISKS OF PROCEDURAL FAILURE (WITHIN 6-WEEKS) AND RECURRENCE (6-WEEKS TO 5-YEARS), DEFINED BY ULTRASOUND, BETWEEN THE DIFFERENT MODALITIES OF INTERVENTION FOR SUPERFICIAL VENOUS INCOMPETENCE. TREATMENT COMPARISONS ADDRESSING RISKS OF COMMON ADVERSE EVENTS, VENOUS CLINICAL SEVERITY SCORE, AND PAIN WERE ALSO PERFORMED. THE REVIEW IDENTIFIED 51 ARTICLES, DESCRIBING 36 RANDOMIZED CONTROLLED TRIALS, INCORPORATING 7576 LIMBS. ENDOVENOUS INTERVENTIONS INCLUDED ENDOVENOUS LASER ABLATION (EVLA), RADIOFREQUENCY ABLATION (RFA), MECHANOCHEMICAL ABLATION (MOCA), ULTRASOUND-GUIDED FOAM SCLEROTHERAPY (FS), AND CYANOACRYLATE ADHESIVE CLOSURE (CAE) WHEREAS OPEN PROCEDURES CONSISTED OF HIGH LIGATION, WITH OR WITHOUT SAPHENOUS STRIPPING, AND CONSERVATRICE HEMODYNAMIQUE DE L¿INSUFFISANCE VEINEUSE EN AMBULATOIRE (CHIVA). HYBRID INTERVENTIONS INCLUDING HIGH LIGATION WITH EITHER TRUNCAL EVLA OR FS WERE ALSO DESCRIBED. NINETEEN RCTS (3774 LIMBS), DESCRIBING 8 INTERVENTIONS, PROVIDED DATA FOR PROCEDURAL FAILURE. ONE STUDY REPORTED NO FAILURE IN EITHER COHORT AND WAS EXCLUDED. CAE SIGNIFICANTLY REDUCED THE ODDS OF PROCEDURAL FAILURE COMPARED TO RFA AND MOCA. EVLA SIGNIFICANTLY REDUCED PROCEDURAL FAILURE COMPARED WITH FS ALONE. FORTY-SEVEN REPORTS, CONTAINING 32 RCTS DESCRIBED DISEASE RECURRENCE. DIRECT AND INDIRECT COMPARISON OF INTERVENTIONS REVEALED THAT THOSE RECEIVING FS WERE SIGNIFICANTLY MORE LIKELY TO EXPERIENCE DISEASE RECURRENCE AT MOST TIME POINTS (EXCEPT 2-YEARS) WHEN COMPARED WITH HIGH LIGATION AND STRIPPING (HLS). PATIENTS RECEIVING EVLA HAD SIGNIFICANTLY MORE RECURRENCES WHEN COMPARED TO HLS AT 2-YEARS ALONE. AT 6 MONTHS CAE RANKED AS THE BEST TREATMENT TO REDUCE RECURRENCE AND WAS STATISTICALLY SUPERIOR TO RFA OR MOCA AND FS. NO SIGNIFICANT DIFFERENCES IN RECURRENCE RATES WERE IDENTIFIED WHEN ENDOVENOUS TECHNIQUES AND HLS WERE COMPARED SAVE THOSE UNDERGOING FS. AT ONE-YEAR, EVLA WITH HIGH LIGATION FOLLOWED BY CAE RANKED FIRST AND SECOND TO REDUCE RECURRENCE RISK AT 1-YEAR. NEITHER INTERVENTION OFFERED SUPERIORITY OVER HLS. FS AGAIN RANKED LAST AND WAS ASSOCIATED WITH SIGNIFICANTLY HIGHER RATES OF RECURRENCE THAN ALL EXCEPT HIGH LIGATION AND FS WITH LIGATION. AT 2-5 YEARS, CHIVA AND HLS RANKED BEST WITH REGARDTO RECURRENCE RATES UP TO 5-YEARS. HLS WAS SUPERIOR TO EVLA AND HIGH LIGATION ALONE AT 2-YEARS AND EVLA BEYOND 2-YEARS. ALL INTERVENTIONS SAVE HIGH LIGATION AND FS WITH LIGATION OFFERED SIGNIFICANTLY LOWER RATES OF RECURRENCE COMPARED TO FS ALONE. TWENTY-NINE REPORTS, CONTAINING 27 RCTS, REPORTED ADVERSE EVENTS. PULMONARY EMBOLISM (PE) WAS RARE WITH ONLY 2 EVENTS REPORTED AMONG 1865 TREATED LIMBS. BOTH AFFECTED PATIENTS UNDERWENT FS. NO INTERVENTION SIGNIFICANTLY REDUCED THE RISK OF DVT. RISKS OF OTHER COMPLICATIONS VARIED DEPENDING ON THE INTERVENTION. HLS INCREASED THE RISK OF HEMATOMA WHEN COMPARED WITH ENDOVENOUS INTERVENTIONS. FS INCREASED THE RISK OF DYSPIGMENTATION WHEN COMPARED TO HLS RESPECTIVELY. FS ALSO INCREASED THE RISK OF PHLEBITIS WHEN COMPARED HLS, AND EVLA WITH LIGATION. ALTHOUGH RFA INCREASED THE RISK OF PARAESTHESIA WHEN COMPARED TO EVLA, CAE, FS WITH AND WITHOUT LIGATION, THE DATA WAS STATISTICALLY INCONSISTENT. NO INTERVENTION SIGNIFICANTLY REDUCED THE RISK OF INFECTION, ECCHYMOSIS, OR THROMBOPHLEBITIS. FIVE RCTS EXAMINED POSTPROCEDURAL PAIN BETWEEN 1-WEEK TO 1-MONTH POSTINTERVENTION SIGNIFICANTLY REDUCED POSTPROCEDURAL PAIN WHEN COMPARED TO ALL OTHER TREATMENT MODALITIES BY 1.3 TO 2.83. RFA AND HLS WERE ALL ASSOCIATED WITH LESS POSTPROCEDURAL PAIN SCORES WHEN COMPARED TO EVLA.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    2436994 CLOSUREFAST CATHETER ELECTROSURGICAL, CUTTING & COAGULATION & ACCES GEI COVIDIEN

    Patients

    Seq Age Sex Outcome Treatment
    1 45 YR Female Required Intervention